Chitosan-Based Nanomaterial As Immune Adjuvant and Delivery Carrier for Vaccines

Overview

Journal Vaccines (Basel)

Date 2022 Nov 24

PMID 36423002

Authors

Xiaochen Gong

Yuan Gao

Jianhong Shu

Chunjing Zhang

Kai Zhao

Affiliations

Soon will be listed here.

Abstract

With the support of modern biotechnology, vaccine technology continues to iterate. The safety and efficacy of vaccines are some of the most important areas of development in the field. As a natural substance, chitosan is widely used in numerous fields-such as immune stimulation, drug delivery, wound healing, and antibacterial procedures-due to its good biocompatibility, low toxicity, biodegradability, and adhesion. Chitosan-based nanoparticles (NPs) have attracted extensive attention with respect to vaccine adjuvants and delivery systems due to their excellent properties, which can effectively enhance immune responses. Here, we list the classifications and mechanisms of action of vaccine adjuvants. At the same time, the preparation methods of chitosan, its NPs, and their mechanism of action in the delivery system are introduced. The extensive applications of chitosan and its NPs in protein vaccines and nucleic acid vaccines are also introduced. This paper reviewed the latest research progress of chitosan-based NPs in vaccine adjuvant and drug delivery systems.

Citing Articles

The Paradoxical Immunomodulatory Effects of Chitosan in Biomedicine.

Reay S, Marina Ferreira A, Hilkens C, Novakovic K Polymers (Basel). 2025; 17(1.

PMID: 39795422 PMC: 11723117. DOI: 10.3390/polym17010019.

A Bibliometric Analysis on Multi-epitope Vaccine Development Against SARS-CoV-2: Current Status, Development, and Future Directions.

Khalid K, Ahmad F, Anwar A, Ong S Mol Biotechnol. 2025; .

PMID: 39789401 DOI: 10.1007/s12033-024-01358-5.

- Challenges and Perspectives in Polyelectrolytes.

Traeger A, Leiske M Biomacromolecules. 2024; 26(1):5-32.

PMID: 39661745 PMC: 11733940. DOI: 10.1021/acs.biomac.4c01061.

Immunogenicity and protective efficacy of an inactivated infectious bronchitis virus vaccine candidate from a local isolate of Bangladesh.

Parvin M, Haque M, Haque M, Kamal M, Sadekuzzaman M, Hayat S J Adv Vet Anim Res. 2024; 11(3):592-600.

PMID: 39605761 PMC: 11590607. DOI: 10.5455/javar.2024.k809.

Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.

Soto-Sanchez J, Garza-Trevino G Pharmaceutics. 2024; 16(10).

PMID: 39458571 PMC: 11510106. DOI: 10.3390/pharmaceutics16101239.

References

Yang Y, Xing R, Liu S, Qin Y, Li K, Yu H . Chitosan, hydroxypropyltrimethyl ammonium chloride chitosan and sulfated chitosan nanoparticles as adjuvants for inactivated Newcastle disease vaccine. Carbohydr Polym. 2019; 229:115423. DOI: 10.1016/j.carbpol.2019.115423. View

Yu Z, Zhou T, Luo Y, Dong L, Li C, Liu J . Modulation Effects of Histone H2A1 on Murine Macrophages and Encapsulation with Polymer as a Vaccine Candidate. Vaccines (Basel). 2020; 8(4). PMC: 7761694. DOI: 10.3390/vaccines8040731. View

Tlaxca J, Ellis S, Remmele Jr R . Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv Drug Deliv Rev. 2014; 93:56-78. DOI: 10.1016/j.addr.2014.10.002. View

Zhang X, Zhao T, Zeng T, Wu N, Xiao Y, Liu S . Intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 and enhanced immunization with mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein effectively induced strong mucosal immune responses and immune protective effects.... Exp Ther Med. 2018; 15(3):2533-2540. PMC: 5795528. DOI: 10.3892/etm.2018.5689. View

Bravo-Anaya L, Fernandez-Solis K, Rosselgong J, Nano-Rodriguez J, Carvajal F, Rinaudo M . Chitosan-DNA polyelectrolyte complex: Influence of chitosan characteristics and mechanism of complex formation. Int J Biol Macromol. 2019; 126:1037-1049. DOI: 10.1016/j.ijbiomac.2019.01.008. View

S K, Nishanth A, Arvind Bharani R S , Nivedh K, Syed N, R R . Hepatitis B-surface antigen (HBsAg) vaccine fabricated chitosan-polyethylene glycol nanocomposite (HBsAg-CS-PEG- NC) preparation, immunogenicity, controlled release pattern, biocompatibility or non-target toxicity. Int J Biol Macromol. 2019; 144:978-994. DOI: 10.1016/j.ijbiomac.2019.09.175. View

Yu X, Wen T, Cao P, Shan L, Li L . Alginate-chitosan coated layered double hydroxide nanocomposites for enhanced oral vaccine delivery. J Colloid Interface Sci. 2019; 556:258-265. DOI: 10.1016/j.jcis.2019.08.027. View

Wan X, Yin Y, Zhou C, Hou L, Cui Q, Zhang X . Polysaccharides derived from Chinese medicinal herbs: A promising choice of vaccine adjuvants. Carbohydr Polym. 2021; 276:118739. DOI: 10.1016/j.carbpol.2021.118739. View

Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q . Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Rev Vaccines. 2017; 16(9):895-906. DOI: 10.1080/14760584.2017.1355733. View

10.

Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R . Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomedicine. 2018; 13:7959-7970. PMC: 6260144. DOI: 10.2147/IJN.S165876. View

11.

Wei Y, Huang Y, Cheng K, Song Y . Investigations of the Influences of Processing Conditions on the Properties of Spray Dried Chitosan-Tripolyphosphate Particles loaded with Theophylline. Sci Rep. 2020; 10(1):1155. PMC: 6981135. DOI: 10.1038/s41598-020-58184-3. View

12.

Hajam I, Senevirathne A, Hewawaduge C, Kim J, Lee J . Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens. Vet Res. 2020; 51(1):37. PMC: 7060564. DOI: 10.1186/s13567-020-00762-4. View

13.

Gumina E, Hall J, Vecchi B, Hernandez-Velasco X, Lumpkins B, Mathis G . Evaluation of a subunit vaccine candidate (Biotech Vac Cox) against Eimeria spp. in broiler chickens. Poult Sci. 2021; 100(9):101329. PMC: 8342787. DOI: 10.1016/j.psj.2021.101329. View

14.

Muflihah H, Florido M, Lin L, Xia Y, Triccas J, Stambas J . Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. PLoS One. 2021; 16(11):e0259829. PMC: 8601556. DOI: 10.1371/journal.pone.0259829. View

15.

Singh V, Kumar S, Dhaked R, Ansari A, Lohiya N, Tapryal S . Generation of oligomers of subunit vaccine candidate glycoprotein D of Herpes Simplex Virus-2 expressed in fusion with IgM Fc domain(s) in : A strategy to enhance the immunogenicity of the antigen. 3 Biotech. 2020; 10(11):463. PMC: 7541101. DOI: 10.1007/s13205-020-02452-6. View

16.

Huang X, Ma Y, Wang Y, Niu C, Liu Z, Yao X . Oral Probiotic Vaccine Expressing Koi Herpesvirus (KHV) ORF81 Protein Delivered by Chitosan-Alginate Capsules Is a Promising Strategy for Mass Oral Vaccination of Carps against KHV Infection. J Virol. 2021; 95(12). PMC: 8315992. DOI: 10.1128/JVI.00415-21. View

17.

Wang T, Zhu X, Yi H, Gu J, Liu S, Izenwasser S . Viral vector-mediated gene therapy for opioid use disorders. Exp Neurol. 2021; 341:113710. DOI: 10.1016/j.expneurol.2021.113710. View

18.

Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M . New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2020; 39(2):197-201. PMC: 7685034. DOI: 10.1016/j.vaccine.2020.11.054. View

19.

Sciullo P, Menay F, Cocozza F, Gravisaco M, Waldner C, Mongini C . Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Clin Immunol. 2019; 203:154-161. DOI: 10.1016/j.clim.2019.04.013. View

20.

Xu Y, Zhou Z, Brooks B, Ferguson T, Obliosca J, Huang J . Layer-by-Layer Delivery of Multiple Antigens Using Trimethyl Chitosan Nanoparticles as a Malaria Vaccine Candidate. Front Immunol. 2022; 13:900080. PMC: 9428560. DOI: 10.3389/fimmu.2022.900080. View